Top

Published in:

01-11-2019 | Esophageal Cancer | Original Article

IL-33 in the tumor microenvironment is associated with the accumulation of FoxP3-positive regulatory T cells in human esophageal carcinomas

Authors: Guanglin Cui, Zhenfeng Li, Jingli Ren, Aping Yuan

Published in: Virchows Archiv | Issue 5/2019

Abstract

Forkhead box p3 (Foxp3⁺) regulatory T cells (Tregs) are abundant in the tumor microenvironment where they dampen functions of host anti-tumor immunity and promote cancer progression. Cytokine signaling is essential for the generation and function maintenance of Tregs in patients with cancers. Recent in vitro and in vivo studies have described that interleukin (IL)-33 plays a critical role in regulating the expansion and function of Tregs. However, the regulatory role of IL-33 in Treg recruitment within the microenvironment of human esophageal squamous cell carcinoma (ESCC) to date is poorly understood. In this study, we have therefore characterized the expression of IL-33 by immunohistochemistry (IHC) and double immunofluorescence staining and analyzed its relationship with FoxP3⁺ Treg accumulation in the microenvironment in 80 patients with ESCC. IHC observation revealed a high expression level of IL-33 in both ESCC mass and stroma, which paralleled to a high density of FoxP3⁺ Tregs accumulated in the same compartments. Statistical analysis showed that the scores for cell densities of tumor- and stroma-expressing IL-33 were significantly correlated with the scores for density of FoxP3⁺ Tregs in the tumor stroma. Further immunofluorescence images demonstrated that IL-33 functional receptor, ST2, was preferentially expressed in FoxP3⁺ Tregs, suggesting a possible effecting pathway for IL-33. In addition, cyclooxygenase-2, one of the important immunosuppressive factors, was highly illustrated in FoxP3⁺ Tregs. We have therefore concluded that microenvironmental-expressing IL-33 is associated with the recruitment of Tregs in human ESCCs.

Cayrol C, Girard JP (2018) Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family. Immunol Rev 281:154–168. https://doi.org/10.1111/imr.12619 CrossRefPubMed

Cui G, Li C, Xu G, Sun Z, Zhu L, Li Z, Zheng W, Li J, Yuan A (2018) Tumor-associated fibroblasts and microvessels contribute to the expression of immunosuppressive factor indoleamine 2, 3-dioxygenase in human esophageal cancers. Pathol Oncol Res : POR 24:269–275. https://doi.org/10.1007/s12253-017-0244-0 CrossRefPubMed

Cui G, Qi H, Gundersen MD, Yang H, Christiansen I, Sorbye SW, Goll R, Florholmen J (2015) Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer cancer immunology. immunotherapy : CII 64:181–190. https://doi.org/10.1007/s00262-014-1624-x CrossRef

Cui G, Ren J, Xu G, Li Z, Zheng W, Yuan A (2018) Cellular and clinicopathological features of the IL-33/ST2 axis in human esophageal squamous cell carcinomas. Cancer Cell Int 18:203. https://doi.org/10.1186/s12935-018-0700-2 CrossRefPubMedPubMedCentral

Cui G, Yuan A, Pang Z, Zheng W, Li Z, Goll R (2018) Contribution of IL-33 to the pathogenesis of colorectal cancer. Front Oncol 8:561. https://doi.org/10.3389/fonc.2018.00561 CrossRefPubMedPubMedCentral

Cui G, Yuan A, Sun Z, Zheng W, Pang Z (2018) IL-1beta/IL-6 network in the tumor microenvironment of human colorectal cancer. Pathol Res Pract 214:986–997. https://doi.org/10.1016/j.prp.2018.05.011 CrossRefPubMed

Cui G, Yuan A, Zhu L, Florholmen J, Goll R (2017) Increased expression of interleukin-21 along colorectal adenoma-carcinoma sequence and its predicating significance in patients with sporadic colorectal cancer. Clin Immunol 183:266–272. https://doi.org/10.1016/j.clim.2017.09.003 CrossRefPubMed

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949. https://doi.org/10.1038/nm1093 CrossRefPubMed

Global Burden of Disease Cancer C, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MF MI, Allen C, Hansen G, Woodbrook R, Wolfe C, Hamadeh RR, Moore A, Werdecker A, Gessner BD, Te Ao B, McMahon B, Karimkhani C, Yu C, Cooke GS, Schwebel DC, Carpenter DO, Pereira DM, Nash D, Kazi DS, De Leo D, Plass D, Ukwaja KN, Thurston GD, Yun Jin K, Simard EP, Mills E, Park EK, Catala-Lopez F, de Veber G, Gotay C, Khan G, Hosgood HD 3rd, Santos IS, Leasher JL, Singh J, Leigh J, Jonas JB, Sanabria J, Beardsley J, Jacobsen KH, Takahashi K, Franklin RC, Ronfani L, Montico M, Naldi L, Tonelli M, Geleijnse J, Petzold M, Shrime MG, Younis M, Yonemoto N, Breitborde N, Yip P, Pourmalek F, Lotufo PA, Esteghamati A, Hankey GJ, Ali R, Lunevicius R, Malekzadeh R, Dellavalle R, Weintraub R, Lucas R, Hay R, Rojas-Rueda D, Westerman R, Sepanlou SG, Nolte S, Patten S, Weichenthal S, Abera SF, Fereshtehnejad SM, Shiue I, Driscoll T, Vasankari T, Alsharif U, Rahimi-Movaghar V, Vlassov VV, Marcenes WS, Mekonnen W, Melaku YA, Yano Y, Artaman A, Campos I, MacLachlan J, Mueller U, Kim D, Trillini M, Eshrati B, Williams HC, Shibuya K, Dandona R, Murthy K, Cowie B, Amare AT, Antonio CA, Castaneda-Orjuela C, van Gool CH, Violante F, Oh IH, Deribe K, Soreide K, Knibbs L, Kereselidze M, Green M, Cardenas R, Roy N, Tillmann T, Li Y, Krueger H, Monasta L, Dey S, Sheikhbahaei S, Hafezi-Nejad N, Kumar GA, Sreeramareddy CT, Dandona L, Wang H, Vollset SE, Mokdad A, Salomon JA, Lozano R, Vos T, Forouzanfar M, Lopez A, Murray C, Naghavi M (2015) The global burden of cancer 2013. JAMA Oncol 1:505–527. https://doi.org/10.1001/jamaoncol.2015.0735 CrossRef

10.

Griesenauer B, Paczesny S (2017) The ST2/IL-33 axis in immune cells during inflammatory diseases. Front Immunol 8:475. https://doi.org/10.3389/fimmu.2017.00475 CrossRefPubMedPubMedCentral

11.

Hua W, Yuan A, Zheng W, Li C, Cui J, Pang Z, Zhang L, Li Z, Goll R, Cui G (2016) Accumulation of FoxP3+ T regulatory cells in the tumor microenvironment of human colorectal adenomas. Pathol Res Pract 212:106–112. https://doi.org/10.1016/j.prp.2015.12.002 CrossRefPubMed

12.

Jovanovic I, Radosavljevic G, Mitrovic M, Juranic VL, McKenzie AN, Arsenijevic N, Jonjic S, Lukic ML (2011) ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol 41:1902–1912. https://doi.org/10.1002/eji.201141417 CrossRefPubMedPubMedCentral

13.

Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, Lukic ML (2014) Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. International journal of cancer. J Int Cancer 134:1669–1682. https://doi.org/10.1002/ijc.28481 CrossRef

14.

Ke L (2002) Mortality and incidence trends from esophagus cancer in selected geographic areas of China circa 1970-90. International journal of cancer J Int Cancer 102:271–274. doi: https://doi.org/10.1002/ijc.10706 CrossRef

15.

Liu B, Qu L, Yan S (2015) Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int 15:106. https://doi.org/10.1186/s12935-015-0260-7 CrossRefPubMedPubMedCentral

16.

Liu J, Li Z, Cui J, Xu G, Cui G (2012) Cellular changes in the tumor microenvironment of human esophageal squamous cell carcinomas. Tumour Biol: J Int Soc Oncodev Biol Med 33:495–505. https://doi.org/10.1007/s13277-011-0281-3 CrossRef

17.

Liu J, Lu G, Li Z, Tang F, Liu Y, Cui G (2010) Distinct compartmental distribution of mature and immature dendritic cells in esophageal squamous cell carcinoma. Pathol Res Pract 206:602–606. https://doi.org/10.1016/j.prp.2010.03.011 CrossRefPubMed

18.

Lu B, Yang M, Wang Q (2016) Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. J Mol Med (Berl) 94:535–543. https://doi.org/10.1007/s00109-016-1397-0 CrossRef

19.

Mahic M, Yaqub S, Johansson CC, Tasken K, Aandahl EM (2006) FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 177:246–254CrossRef

20.

Mandarano M, Bellezza G, Belladonna ML, Van den Eynde BJ, Chiari R, Vannucci J, Mondanelli G, Ludovini V, Ferri I, Bianconi F, Del Sordo R, Cagini L, Albini E, Metro G, Puma F, Sidoni A (2019) Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. Virchows Arch 474:159–168. https://doi.org/10.1007/s00428-018-2483-1 CrossRefPubMed

21.

Nabeki B, Ishigami S, Uchikado Y, Sasaki K, Kita Y, Okumura H, Arigami T, Kijima Y, Kurahara H, Maemura K, Natsugoe S (2015) Interleukin-32 expression and Treg infiltration in esophageal squamous cell carcinoma. Anticancer Res 35:2941–2947PubMed

22.

Nascimento DC, Melo PH, Pineros AR, Ferreira RG, Colon DF, Donate PB, Castanheira FV, Gozzi A, Czaikoski PG, Niedbala W, Borges MC, Zamboni DS, Liew FY, Cunha FQ, Alves-Filho JC (2017) IL-33 contributes to sepsis-induced long-term immunosuppression by expanding the regulatory T cell population. Nat Commun 8:14919. https://doi.org/10.1038/ncomms14919 CrossRefPubMedPubMedCentral

23.

Peine M, Marek RM, Lohning M (2016) IL-33 in T cell differentiation, function, and immune homeostasis. Trends Immunol 37:321–333. https://doi.org/10.1016/j.it.2016.03.007 CrossRefPubMed

24.

Popovic B, Golemac M, Podlech J, Zeleznjak J, Bilic-Zulle L, Lukic ML, Cicin-Sain L, Reddehase MJ, Sparwasser T, Krmpotic A, Jonjic S (2017) IL-33/ST2 pathway drives regulatory T cell dependent suppression of liver damage upon cytomegalovirus infection. PLoS Pathog 13:e1006345. https://doi.org/10.1371/journal.ppat.1006345 CrossRefPubMedPubMedCentral

25.

Reisenbichler ES, Dupont W, Plummer WD, Hameed O (2017) Is tumor cellularity in primary invasive breast carcinoma of prognostic significance? Virchows Arch 470:611–617. https://doi.org/10.1007/s00428-017-2120-4 CrossRefPubMed

26.

Sakaguchi S, Miyara M, Costantino CM, Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10:490–500. https://doi.org/10.1038/nri2785 CrossRefPubMed

27.

Schiering C, Krausgruber T, Chomka A, Frohlich A, Adelmann K, Wohlfert EA, Pott J, Griseri T, Bollrath J, Hegazy AN, Harrison OJ, Owens BMJ, Lohning M, Belkaid Y, Fallon PG, Powrie F (2014) The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513:564–568. https://doi.org/10.1038/nature13577 CrossRefPubMedPubMedCentral

28.

Shi Y, Li Z, Zheng W, Liu X, Sun C, Laugsand JB, Liu Z, Cui G (2015) Changes of immunocytic phenotypes and functions from human colorectal adenomatous stage to cancerous stage: update. Immunobiology 220:1186–1196. https://doi.org/10.1016/j.imbio.2015.06.003 CrossRefPubMed

29.

Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K (2010) Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 5:585–590. https://doi.org/10.1097/JTO.0b013e3181d60fd7 CrossRefPubMed

30.

Stein AV, Dislich B, Blank A, Guldener L, Kroll D, Seiler CA, Langer R (2017) High intratumoural but not peritumoural inflammatory host response is associated with better prognosis in primary resected oesophageal adenocarcinomas. Pathology 49:30–37. https://doi.org/10.1016/j.pathol.2016.10.005 CrossRefPubMed

31.

Strand S, Galle PR (1998) Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today 4:63–68. https://doi.org/10.1016/S1357-4310(97)01191-X CrossRefPubMed

32.

Sun DS, Zhao MQ, Xia M, Li L, Jiang YH (2012) The correlation between tumor-infiltrating Foxp3+ regulatory T cells and cyclooxygenase-2 expression and their association with recurrence in resected head and neck cancers. Med Oncol 29:707–713. https://doi.org/10.1007/s12032-011-9903-2 CrossRefPubMed

33.

Toomer KH, Malek TR (2018) Cytokine signaling in the development and homeostasis of regulatory T cells. Cold Spring Harb Perspect Biol 10:a028597. https://doi.org/10.1101/cshperspect.a028597 CrossRefPubMed

34.

Vacchelli E, Semeraro M, Adam J, Dartigues P, Zitvogel L, Kroemer G (2016) Immunosurveillance in esophageal carcinoma: the decisive impact of regulatory T cells. Oncoimmunology 5:e1064581. https://doi.org/10.1080/2162402X.2015.1064581 CrossRefPubMed

35.

van Pelt GW, Kjaer-Frifeldt S, van Krieken J, Al Dieri R, Morreau H, Tollenaar R, Sorensen FB, Mesker WE (2018) Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations. Virchows Arch 473:405–412. https://doi.org/10.1007/s00428-018-2408-z CrossRefPubMedPubMedCentral

36.

Whiteside TL (2012) What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 22:327–334. https://doi.org/10.1016/j.semcancer.2012.03.004 CrossRefPubMedPubMedCentral

37.

Whiteside TL (2014) Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin Biol Ther 14:1411–1425. https://doi.org/10.1517/14712598.2014.927432 CrossRefPubMedPubMedCentral

38.

Xu X, Song C, Chen Z, Yu C, Wang Y, Tang Y, Luo J (2018) Downregulation of HuR inhibits the progression of esophageal cancer through interleukin-18. Cancer Res Treat: Off J Korean Cancer Assoc 50:71–87. https://doi.org/10.4143/crt.2017.013 CrossRef

39.

Yukawa T, Shimizu K, Maeda A, Yasuda K, Saisho S, Okita R, Nakata M (2015) Cyclooxygenase-2 genetic variants influence intratumoral infiltration of Foxp3-positive regulatory T cells in non-small cell lung cancer. Oncol Rep 33:74–80. https://doi.org/10.3892/or.2014.3561 CrossRefPubMed

40.

Zhu J, Xu Y, Zhu C, Zhao J, Meng X, Chen S, Wang T, Li X, Zhang L, Lu C, Liu H, Sun X (2017) IL-33 induces both regulatory B cells and regulatory T cells in dextran sulfate sodium-induced colitis. Int Immunopharmacol 46:38–47. https://doi.org/10.1016/j.intimp.2017.02.006 CrossRefPubMed

Title: IL-33 in the tumor microenvironment is associated with the accumulation of FoxP3-positive regulatory T cells in human esophageal carcinomas
Authors: Guanglin Cui
Zhenfeng Li
Jingli Ren
Aping Yuan
Publication date: 01-11-2019
Publisher: Springer Berlin Heidelberg
Keywords: Esophageal Cancer
Esophageal Cancer
Published in: Virchows Archiv / Issue 5/2019
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-019-02579-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

IL-33 in the tumor microenvironment is associated with the accumulation of FoxP3-positive regulatory T cells in human esophageal carcinomas

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2019

Polyomavirus JCPyV infrequently detectable in adenoid cystic carcinoma of the oral cavity and the airways

In this issue

Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays

IDH1 immunohistochemistry reactivity and mosaic IDH1 or IDH2 somatic mutations in pediatric sporadic enchondroma and enchondromatosis

Identification of barriers and facilitators in nationwide implementation of standardized structured reporting in pathology: a mixed method study

Mist1: a novel nuclear marker for acinic cell carcinoma of the salivary gland